SCHEMBL23300656

SCHEMBL23300656

NC1CC(c2ccc(Cl)nc2F)C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 3/20 0.36
CHRNA4 P43681 3/20 0.36
HTR3E A5X5Y0 1/20 0.36
MEN1 O00255 1/20 0.36
HTR3B O95264 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
NFKB1 P19838 1/20 0.36
HTR3A P46098 1/20 0.36
KMT2A Q03164 1/20 0.36
HTR3D Q70Z44 1/20 0.36
HTR3C Q8WXA8 1/20 0.36
PIM2 Q9P1W9 10/20 0.33
PIM1 P11309 8/20 0.32
PIM3 Q86V86 8/20 0.32
GSK3B P49841 1/20 0.31
PRKCQ Q04759 1/20 0.31
KCNH2 Q12809 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28823323 0.98 CHRNB2 (0.36) CHRNB2CHRNA4HTR3EMEN1HTR3B
SCHEMBL31003182 0.81 CHRNB2 (0.37) CHRNB2CHRNA4HTR3EMEN1HTR3B
SCHEMBL23329503 0.79 KDM1A (0.36) PIM2KCNH2
Hydrochloric Acid SCHEMBL31289637 0.76 ALOX5AP (0.37) CHRNB2CHRNA4
SCHEMBL31361235 0.69 NPC1 (0.38) CHRNB2CHRNA4TSHR
SCHEMBL9154511 0.67 TRPV3 (0.33) CHRNB2CHRNA4
SCHEMBL9154516 0.67 TRPV3 (0.33) CHRNB2CHRNA4
SCHEMBL9154527 0.67 TRPV3 (0.33) CHRNB2CHRNA4
SCHEMBL9154514 0.67 TRPV3 (0.33) CHRNB2CHRNA4
SCHEMBL31361249 0.67 CHRNB2 (0.32) CHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230012600-A1 BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVES AND USES THEREOF BROADENBIO CO., LTD. (CN) 2023-01-19 US disclosed
WO-2021083011-A1 BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVE AND USE THEREOF 北京伯汇生物技术有限公司 2021-05-06 WO disclosed
WO-2021083011-A1 BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVE AND USE THEREOF 北京伯汇生物技术有限公司 2021-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230012600-A1 BRIDGED CYCLOFORMYLPYRIDINE DERIVATIVES AND USES THEREOF FGFR4, FGFR1, FGFR3 CHRNB2 4282/4885CHRNA4 2510/4885HTR3E 3664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.